Moody Aldrich Partners LLC Purchases 9,625 Shares of Kymera Therapeutics, Inc. $KYMR

Moody Aldrich Partners LLC grew its position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 33.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 38,535 shares of the company’s stock after buying an additional 9,625 shares during the quarter. Moody Aldrich Partners LLC owned 0.05% of Kymera Therapeutics worth $2,998,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Pictet Asset Management Holding SA lifted its holdings in shares of Kymera Therapeutics by 39.3% during the 4th quarter. Pictet Asset Management Holding SA now owns 483,199 shares of the company’s stock valued at $37,791,000 after buying an additional 136,382 shares during the period. UBS Group AG lifted its holdings in shares of Kymera Therapeutics by 13.6% during the 4th quarter. UBS Group AG now owns 737,032 shares of the company’s stock valued at $57,348,000 after buying an additional 88,314 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Kymera Therapeutics by 15.6% during the 4th quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock valued at $487,685,000 after buying an additional 845,922 shares during the period. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Kymera Therapeutics by 8.8% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 24,524 shares of the company’s stock valued at $1,908,000 after buying an additional 1,992 shares during the period. Finally, Arizona State Retirement System lifted its holdings in shares of Kymera Therapeutics by 6.9% during the 4th quarter. Arizona State Retirement System now owns 13,284 shares of the company’s stock valued at $1,034,000 after buying an additional 853 shares during the period.

Insiders Place Their Bets

In other Kymera Therapeutics news, COO Jeremy G. Chadwick sold 300 shares of the stock in a transaction on Wednesday, April 22nd. The stock was sold at an average price of $90.00, for a total value of $27,000.00. Following the completion of the sale, the chief operating officer owned 61,202 shares in the company, valued at approximately $5,508,180. This represents a 0.49% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Bruce Booth sold 5,900 shares of the stock in a transaction on Wednesday, April 22nd. The stock was sold at an average price of $89.96, for a total value of $530,764.00. Following the completion of the sale, the director owned 5,641 shares of the company’s stock, valued at $507,464.36. The trade was a 51.12% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 350,734 shares of company stock worth $29,758,502. Corporate insiders own 16.01% of the company’s stock.

Kymera Therapeutics Stock Performance

Shares of KYMR stock opened at $83.85 on Wednesday. Kymera Therapeutics, Inc. has a 52-week low of $28.06 and a 52-week high of $103.00. The firm has a market capitalization of $6.85 billion, a PE ratio of -22.79 and a beta of 2.28. The stock has a fifty day simple moving average of $84.70 and a two-hundred day simple moving average of $76.16.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.20). Kymera Therapeutics had a negative return on equity of 28.71% and a negative net margin of 794.04%.The business had revenue of $2.87 million during the quarter, compared to analysts’ expectations of $14.80 million. During the same quarter in the previous year, the company posted ($0.88) EPS. The company’s quarterly revenue was down 60.8% on a year-over-year basis. On average, sell-side analysts forecast that Kymera Therapeutics, Inc. will post -3.65 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Wall Street Zen cut Kymera Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Barclays increased their price target on Kymera Therapeutics to $133.00 and gave the company an “overweight” rating in a report on Tuesday, January 27th. UBS Group raised their target price on Kymera Therapeutics from $90.00 to $128.00 and gave the stock a “buy” rating in a report on Tuesday, March 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kymera Therapeutics in a report on Tuesday, April 21st. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $108.00 target price on shares of Kymera Therapeutics in a report on Thursday, February 26th. One analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $118.90.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.